Metabasis, Sankyo start phase 2b trial for type 2 diabetes

By Lisa Kerner

Erie, Pa., Feb. 1 - Metabasis Therapeutics, Inc. said its strategic partner, Sankyo Co., Ltd., has begun a multi-center, double-blind, placebo controlled phase 2b trial to evaluate the safety and efficacy of CS-917 for the treatment of type 2 diabetes.

Sankyo is Metabasis' licensee for CS-917 and funds and directs the clinical development of the drug, according to a company news release.

Patients in the study will receive CS-917, placebo or an active comparator for three months. CS-917 is a first-in-class, orally active inhibitor of FBPase, an enzyme that regulates production of glucose in the liver.

Previously completed phase 2a clinical trials involved a total of 185 patients with type 2 diabetes treated with CS-917. The studies showed clinically and statistically significant reductions in blood sugar levels, the company said.

Once developed, CS-917 is expected to be used alone or in combination with other diabetes therapies.

Metabasis is a biopharmaceutical company based in San Diego.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.